Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Moolec Science ( (MLEC) ) has issued an announcement.
On December 16, 2025, Moolec Science SA held a virtual extraordinary general meeting of shareholders where two key resolutions were approved. The first resolution involved a share consolidation at a ratio of 1-for-10 to 1-for-25, effective between December 17, 2025, and May 14, 2026. The second resolution approved the adoption of amended and restated memorandum and articles of association to reflect the share consolidation. These changes are expected to impact the company’s share structure and governance.
The most recent analyst rating on (MLEC) stock is a Sell with a $3.00 price target. To see the full list of analyst forecasts on Moolec Science stock, see the MLEC Stock Forecast page.
Spark’s Take on MLEC Stock
According to Spark, TipRanks’ AI Analyst, MLEC is a Underperform.
Moolec Science faces significant financial challenges with negative profitability and cash flow issues despite revenue growth. The technical analysis is bearish, and the valuation appears unfavorable with a negative P/E ratio. These factors contribute to a low overall stock score, highlighting the need for improved financial performance and market sentiment.
To see Spark’s full report on MLEC stock, click here.
More about Moolec Science
Moolec Science SA is a company incorporated under the laws of the Cayman Islands, operating in the biotechnology sector. The company is listed on NASDAQ under the ticker MLEC and focuses on innovative scientific solutions, although specific products or services are not detailed in the release.
Average Trading Volume: 163,100
Technical Sentiment Signal: Sell
Current Market Cap: $4.74M
See more insights into MLEC stock on TipRanks’ Stock Analysis page.